O ptic nerve hypoplasia syndrome (ONH) (also referred to as septo-optic dysplasia, SOD) represents a clinical spectrum associated with visual, pituitary, and severe central nervous system structural abnormalities (1, 2) . Traditionally, the cardinal features of the controversial term, SOD, involved 2 or more of the following: (1) pituitary hypoplasia with isolated or combined pituitary hormone deficiencies, (2) ONH, and/or (3) midline brain defects. Risk factors include maternal exposure to recreational or prescription drugs, alcohol, diabetes, and viral infection. Mutations in genes encoding transcription factors that regulate eye, forebrain, and pituitary development have been identified in a small proportion of patients with ONH with hypopituitarism (1). HESX1 homeobox 1 (HESX1) encodes a homeobox protein involved in forebrain and early pituitary development in mice. Mutations in HESX1 account for less than 1% of hypopituitarism ± ONH. An increasing number of genes implicated in ONH have been reported and include other transcription factors important for eye and forebrain development (OTX2, SOX2, PAX6, NR2F1, VAX1, and ATOH7), whereas others identified regulate cellular processes such as RNA splicing, chromatin remodeling, and the microtubular network (1) .
Compound heterozygous mutations in LAMB2, encoding laminin β2, an extracellular matrix glycoprotein, were herein identified in a patient with 3 cardinal features of an ONH associated with growth hormone (GH) deficiency phenotype who also had proteinuric kidney disease. Screening for albuminuria may lead to further identification of LAMB2 mutations in genetically undefined ONH diagnoses.
Methods
Ethics approval was obtained from the Great Ormond Street Hospital NHS Foundation Trust. Following informed consent for genetic testing, targeted next-generation sequencing of ACTN4, ADCK4, CD2AP, COQ2, COQ6, INF2, ITGA3, LAMB2, LMX1B, MYO1E, NPHS1, NPHS2, PDSS2, PLCE1, PTPRO, SMARCAL1, TRPC6, and WT1 was undertaken for nephrotic syndrome and HESX1. Patient and control kidney sections were stained with anti-laminin β2 (1:500, AMAb91096, Atlas) and anti-Podocin antibodies (1:100, P0372, Sigma) as previously described (3) . Pituitary tissue of Lamb2 -/and Lamb2 +/+ mice (4) were stained with hematoxylin and eosin (H&E) and 3,3'-diaminobenzidine (DAB) as previously described (3).
Case History
A male infant presented at age 4 months with roving eye movements and impaired visual function. Born at 35 weeks' gestation to a healthy mother age 33 years, he weighed 1.93 kg (-1.47 SD score [SDS]) and measured 42 cm (-2.13 SDS). No exposure to recreational drugs, alcohol, or prescription medications was reported, and his parents were nonconsanguineous. By age 31 months, he had global developmental delay with marked hypotonia. Cranial magnetic resonance imaging revealed bilateral hypoplastic intraorbital optic nerves and anterior pituitary hypoplasia with a global reduction of white matter. The bulk of the posterior corpus callosum was reduced ( Fig. 1A) . The septum pellucidum was present.
At age 5 years, he presented with recurrent macroscopic hematuria associated with hypoalbuminemia (25 g/L) and significant albuminuria (urine albumin to creatinine ratio was 1329 mg/mmol) with normal renal function. A renal biopsy showed focal segmental glomerulosclerosis (FSGS) and a thin, lamellated glomerular basement membrane (GBM) with podocyte foot process effacement ( Fig. 1B) .
On follow-up, the patient had short stature: His height was 117.7 cm (-1.4 SDS) with a weight of 18.5 kg (-2.54 SDS) at the chronological age of 7.9 years (Fig. 1C ). Investigations revealed a low insulin-like growth factor 1 (IGF1) of 29 ng/mL and normal insulin-like growth factor-binding protein 3 (2.48 ng/L), normal thyroxine and thyrotropin, with a low free 3,5,3′-triiodothyronine of 5.3 pmol/L (6.2-9.5 pmol/L). A glucagon stimulation test revealed a peak GH concentration of 4.5 μg/L, suggesting GH insufficiency. At the start of the test, the basal glucose was 2.8 mmol/L with a nadir of 2.3 mmol/L, reflecting significant hypoglycemia. The peak cortisol to glucagon stimulation testing was normal, measuring 819 nmol/L. Measured prolactin concentrations ranged between 80 and 244 mU/L (normal: 44-479 mU/L). At a chronological age of 10.5 years, the patient's bone age was delayed at 9 years, and therefore the low IGF1 could not be solely accounted for by undernutrition. Given the features of GH insufficiency along with his poor height velocity at 3.7 cm per year with a low IGF1 and neuroradiological findings, daily subcutaneous GH injections at 10 IU/m 2 /week were commenced (Fig. 1C ). Following commencement of GH, his growth rate initially improved to 6.6 cm per year from a growth rate of 3.7 cm per year before commencement of GH. We suspect that adherence to GH treatment may have been an issue initially. Following transfer of the patient's care to his grandparents, the excellent growth rate observed from age 12 years occurred while he was still prepubertal. At age 12.74 years, his height velocity was 10.6 cm per year, with pubertal ratings of G2 P1 A1 and testicular volumes of 2 mL on the right and 3 mL on the left. His bone age at that stage was 10.4 years.
Genetic testing for nephrotic syndrome revealed compound heterozygous missense mutations in LAMB2, the gene encoding laminin β2, a structural component of the GBM, previously implicated in Pierson syndrome (OMIM 609049) (5) (Fig. 1D ). One mutation in exon 7 (c.737G>A, p.Arg246Gln) was originally reported (5) , and the other, identified in exon 25 (c.3982 G>C, p.Gly1328Arg), was novel. Both variants were predicted to be deleterious to protein function using PolyPhen and SIFT software analyses ( Fig. 1E ) and affected highly conserved amino acids (Fig. 1F) . No mutations were detected in HESX1, and the clinical phenotype did not match that documented for SOX2 or OTX2 mutations. Reduced glomerular expression of laminin β2 was observed in the patient biopsy compared to the control (Fig. 1G) .
H&E staining of pituitary sections of Lamb2 -/mice suggested abnormal morphology of the anterior pituitary parenchyma, exhibited by cellular clusters that were not evident in their wild-type littermates ( Fig. 2A) . Somatropin signal was absent in Lamb2 -/compared to Lamb2 +/+ pituitaries (Fig. 2B ). Because the patient had isolated GH deficiency, analysis of other pituitary cell types was not undertaken.
Discussion
Following presentation with recurrent macroscopic hematuria and albuminuria, compound heterozygous mutations in LAMB2, encoding laminin β2, were identified in a boy with short stature, visual impairment, and developmental delay. Investigations revealed ONH associated with anterior pituitary hypoplasia and GH deficiency. Although the septum pellucidum was present, dysgenesis of the posterior corpus callosum was evident, thereby supporting the traditional diagnosis of ONH with GH deficiency and midline defects. Several publications have highlighted that ONH with hypopituitarism now represents a spectrum of developmental defects involving the eye, neural retina, and forebrain (including the pituitary) with a range of midline defects that do not always involve an absent septum pellucidum.
Albuminuria associated with FSGS has not yet been reported in the ONH spectrum. Interestingly, nonsense and truncating mutations in LAMB2 are associated with Pierson syndrome, an autosomal recessive disorder characterized by congenital nephrotic syndrome, ocular abnormalities (commonly microcoria), muscular hypotonia, and neurological deficits (5, 6) . Indeed, Pierson syndrome may be within the ONH spectrum. Hypomorphic missense mutations have been reported with milder phenotypes, manifesting later in childhood, whereby defective secretion of the mutant laminin β2-trimer leads to compromised GBM integrity (7) . The other variant (p.G1328R) is a novel missense mutation, in which glycine is replaced by an arginine at amino acid 1328 in the coiled coil domain of the peptide. Supporting evidence for a pathogenic mutant laminin β2 protein was the finding of a thin GBM on electron microscopy and reduced glomerular laminin β2 expression on patient kidney sections.
To date, genes implicated in ONH play a role in the transcriptional regulation of pituitary and forebrain development (1) . In situ hybridization studies have revealed expression of laminin isoforms throughout pituitary morphogenesis (8, 9) . In early murine gestation, laminin β2 messenger RNA is expressed in the epithelium of the Rathke pouch and by mid-gestation within the pars distalis and tuberalis (9) . Expression later extends to the parenchyma and marginal cell layers of the anterior and intermediate pituitary lobes as well as the vasculature of the anterior lobe, both in late gestation and the early postnatal period (9) . Laminin β2 expression is observed within the parenchyma and vasculature of the anterior lobe in the adult pituitary (9) .
Our examination of Lamb2 -/mice revealed abnormal parenchymal morphology of the anterior pituitary compared to controls, and Lamb2 -/mice exhibit stunted growth (4, 10) . Further investigations involving assessment of pituitary function with measurement of GH levels will be of interest. In Lamb2 -/mice the outer segment of the rod photoreceptor layer is associated with disorganized synapses in the outer plexiform layer and a reduced physiological response (4, 10) . Human and murine findings both support the proposal that mutations in LAMB2 may underlie genetically undefined ONH, and urine dipstick testing may alert the clinician to screen for mutations in LAMB2.
